Robert W. Anderson, M.D., MBA
Dr. Anderson is the David C. Sabiston, Jr. Professor of Surgery at Duke University Medical Center and also served as Chairman of the Department of Surgery at that institution for eight years, until 2003. Dr. Anderson's research interests include cardiovascular surgery and physiology, pulmonary physiology, myocardial function and ventricular mechanics, and the economics of surgical care. Dr. Anderson is an opinion-leading surgeon in his field and is recognized both nationally and internationally for his accomplishments.

Carrie Cox, CEO
Ms. Cox most recently served as Executive Vice President and President, Global Pharmaceuticals, at Schering-Plough Corporation, from 2003 until its merger with Merck & Co., Inc., in November 2009. In that role, she was responsible for the company's global prescription pharmaceutical business, which generated approximately $16 billion in annual sales, with a five year CAGR of 22%. Prior to that, she held a similar role as President, Global Prescription Business at Pharmacia Corporation. Previously, Cox served as SVP of Global Business Management at Pharmacia & Upjohn (the predecessor company to Pharmacia), and as VP of Women's Healthcare at Wyeth-Ayerst. Cox spent her early career at Sandoz pharmaceuticals (now Novartis) in a variety of commercial roles of increasing responsibility.

Cox currently serves on the Boards of Directors of Texas Instruments, Cardinal Health and Celgene. Cox has been named six times to FORTUNE Magazine's list of the "50 Most Powerful Women in Business." Her work has been featured in the Harvard Business Review and in the New York Times bestseller, The Profit Zone. She received her B.S. from Massachusetts College of Pharmacy, and worked for several years in retail and hospital pharmacy.

Brady W. Dougan, MBA
Mr. Dougan is the Chief Executive Officer of Credit Suisse. Prior to holding this position, he was Co- President, Institutional Securities of Credit Suisse where he oversaw day-to-day management and strategy of Credit Suisse First Boston's equity, fixed income, investment banking, private client services and alternative capital businesses. Mr. Dougan received a BA in economics in 1981 and an MBA in finance in 1982 from the University of Chicago.

Robert Langer, Ph.D., Professor,
Massachusetts Institute of Technology
Dr. Langer is one of 13 Institute Professors (the highest honor awarded to a faculty member) at MIT. Dr. Langer has written over 950 articles and has more than 600 issued or pending patents worldwide, one of which was cited as the outstanding patent in Massachusetts in 1988 and one of 20 outstanding patents in the United States. Dr. Langer’s patents have been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology and medical device companies; a number of these companies were launched on the basis of these patent licenses. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 -- 2002 and as Chairman from 1999-2002. During his career, Dr. Langer has received over 150 major awards with the most recent being the United States National Medal of Science.

Dr. Laura Niklason, M.D., Ph.D., Founder and CSO
Dr. Laura Niklason, the Company's scientific founder, is a world leader in tissue engineering. Her research has appeared in some of the most highly regarded peer-reviewed scientific publications, including the journals Science and The Lancet. Dr. Niklason is currently Associate Professor of Anesthesia and Biomedical Engineering at Yale University. Dr. Niklason received her PhD in Biophysics from the University of Chicago and her MD from the University of Michigan. She performed her postdoctoral work at MIT in Dr. Robert Langer's laboratory.

Max Wallace, JD
Mr. Wallace is a Senior Fellow in Innovation and Leadership at the Kenan Institute for Emerging Issues at the University of North Carolina at Chapel Hill. Previously, Mr. Wallace was President and CEO of Cogent Neuroscience, an early-stage biopharmaceutical company developing therapies for neurological diseases. Before starting Cogent, Mr. Wallace was a co-founder of Trimeris, Inc., a public anti-viral research company. He also co-founded Duke Management Company; Sphinx Pharmaceuticals Corporation; SARCO, Inc.; and Mind in Motion, a private multimedia production company. Mr. Wallace received a bachelor's degree from Duke University and a JD from the University of Florida.